Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $216.3 million.

  • Amphastar Pharmaceuticals' Cash & Equivalents rose 1257.0% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.3 million, marking a year-over-year increase of 1257.0%. This contributed to the annual value of $151.6 million for FY2024, which is 506.81% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Cash & Equivalents stood at $216.3 million for Q3 2025, which was up 1257.0% from $187.7 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash & Equivalents peaked at $266.8 million during Q3 2023, and registered a low of $101.6 million during Q1 2021.
  • Its 5-year average for Cash & Equivalents is $165.8 million, with a median of $166.2 million in 2022.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Cash & Equivalents surged by 7915.89% in 2021, and later crashed by 2798.66% in 2024.
  • Amphastar Pharmaceuticals' Cash & Equivalents (Quarter) stood at $126.4 million in 2021, then rose by 23.54% to $156.1 million in 2022, then fell by 7.56% to $144.3 million in 2023, then rose by 5.07% to $151.6 million in 2024, then surged by 42.65% to $216.3 million in 2025.
  • Its Cash & Equivalents stands at $216.3 million for Q3 2025, versus $187.7 million for Q2 2025 and $182.8 million for Q1 2025.